3629 |
Bioresorbable Scaffolds: Rethinking All Mechanism of Scaffold Thrombosis and How to Fix It? |
Yoshinobu Onuma |
Apr. 28. 18 |
3628 |
Compared to Medical Therapy, Does CTO PCI Improve Prognosis, or Are the Main Benefits Symptomatic Improvement? |
Barry D. Rutherford |
Apr. 28. 18 |
3627 |
The Lesson from DECISION-CTO Trial |
Seung-Jung Park |
Apr. 28. 18 |
3626 |
The Lesson from EURO CTO Trial |
Gerald Werner |
Apr. 28. 18 |
3625 |
ISR CTO: What Is the Difference from De Novo CTO? |
Kenya Nasu |
Apr. 28. 18 |
3624 |
CTO with LV Dysfunction: Approaches and Outcomes |
Kambis Mashayekhi |
Apr. 28. 18 |
3623 |
Current Prospective on Iliac Aneurysm Management |
I-Ming Chen |
Apr. 28. 18 |
3622 |
Iliac Arterial Aneurysm: What We Need to Consider and How We Treat It. |
Woong Chol Kang |
Apr. 28. 18 |
3621 |
TEVAR for Chronic Dissections-Strategy for Long-term Durability |
Young-Guk Ko |
Apr. 28. 18 |
3620 |
Long-term Outcome of TEVAR in Acute Type B Dissection |
Han Cheol Lee |
Apr. 28. 18 |